Navigation Links
Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis

FOSTER CITY, Calif.--(BUSINESS WIRE)--May 29, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its Phase III AIR-CF1 (CP-AI-007) study of aztreonam lysine for inhalation for the treatment of people with cystic fibrosis (CF) who have pulmonary Pseudomonas aeruginosa (P. aeruginosa) met its primary efficacy endpoint of change at Day 28 from baseline in respiratory symptoms, as assessed by the Cystic Fibrosis Questionnaire-Revised (CFQ-R), a patient-reported outcome (PRO) tool used to measure health-related quality of life for people with CF. Data from the 164-patient, double-blinded, randomized study demonstrated a significant improvement in the CFQ-R, with a treatment difference in mean change from baseline of 9.7 points in the respiratory domain (on a scale of 100) compared to placebo (p less than 0.001) following a 28-day treatment course with 75 mg aztreonam lysine for inhalation or volume-matched placebo administered three times daily by the PARI eFlow(R) Electronic Nebulizer. Aztreonam lysine-treated patients also experienced significant improvements at Day 28 in respiratory function, as measured by relative improvement of FEV1, with a treatment difference in mean change from baseline of 10.3 percent versus placebo (p less than 0.001). Full study results will be submitted for presentation at an upcoming scientific meeting.

The most common treatment-emergent adverse events in this study were cough, productive cough, nasal congestion, sore throat and dyspnea (shortness of breath). The incidences of these events were not significantly different between the placebo and the aztreonam lysine groups.

"The FDA, Cystic Fibrosis Foundation and medical community have identified PROs as important endpoints in clinical trials for CF and a variety of other diseases," said A. Bruce Montgomery, MD, Senior Vice President, Head of Respiratory Therapeutics, Gilead Sciences. "AIR-CF1 is the first Phase II
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
5. Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... BEVERLY HILLS, Calif. , Jan. 14, 2014 The Brandeis ... Los Angeles a premier and affordable laser tattoo ... treatment special. Dr. Brandeis, focus is in providing high quality cosmetic ... to all patients. " Southern California ...
(Date:1/14/2014)... 14, 2014 NineSigma , Inc., the leading ... Innovation Leadership Summit , May 14-16, 2014 at the ... Ohio . This is the ... to breakthrough achievements through open innovation. Participants will learn ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 2DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 3DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 4DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 5DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 6HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 2HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 3HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 4HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 5HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 6HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 7
(Date:4/18/2014)... Harvard neuroscientists have made a discovery that turns 160 ... electrical insulating material long known to be essential for ... nerve cells, is not as ubiquitous as thought, according ... of the Harvard Stem Cell Institute (HSCI) and the ... collaboration with Professor Jeff Lichtman, of Harvard,s Department of ...
(Date:4/18/2014)... (April 18, 2014) ― A new study in the ... patterns in health-related Google searches reveals a recurring pattern ... , Investigators from San Diego State University, ... Monday Campaigns, analyzed "healthy" Google searches (searches that included ... diet") originating in the U.S. from 2005 to 2012. ...
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... Researchers at the University of California, San Diego School ... those who have suffered a recent major loss are ... older adults. , The study is published in this ... Psychiatry . , Because compassionate behaviors are associated with ... findings offer insights into ways to improve the outcomes ...
(Date:4/17/2014)... personnel who served in Iraq and Afghanistan and ... (TBI) were compared to military personnel without TBI ... in measures of overall disability, cognitive function, post-traumatic ... reported in an article in Journal of ... Liebert, Inc., publishers. The article is available free ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New research shows people are thinking about their health early in the week 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2
... pulmonary embolisma potential life-threatening blockage in a lung arteryshould ... than a CT (computed tomography) angiogram, conclude authors in ... Medicine. , A V/Q scan can be the first ... a pulmonary embolism, noted H. Dirk Sostman, a professor ...
... health care, the SNM Technologist Section recently revised ... Technologist 2007. The updated, forward-looking scopewith its primary ... evolving nature of technology and scienceclearly defines a ... and molecular imaging. , Scope of practice ...
... be compromised by new provisions enabling commercial companies to ... , A study, led by the Centre for International ... that, as a result of changes to how ... to provide patients with integrated and comprehensive services. , ...
... Sept. 7 A new gift line of 19,aromatherapy ... and,Chill Out(TM) has been introduced by Aromatherapy Interventions(TM), a,Newport ... serious aromacology, the science of scent,",says John McKee, CEO, ... Citing Frankincense as an example, McKee notes the scent ...
... Strong Revenue Growth, Driven by Growing Demand for ... Corporate Performers, CHICAGO, Sept. 7 Allscripts ... software, connectivity and information,solutions that physicians use to ... of FORTUNE magazine,s 100 Fastest-Growing Companies for,2007. The ...
... Anthem Blue Cross and Blue Shield in Indiana for ... (NYSE: WLP ) and,M-Plan, Inc., an Indiana-based managed ... Cross and Blue Shield of Indiana as,the insurer of ... exits the,commercial HMO business. WellPoint and M-Plan have entered ...
Cached Medicine News:Health News:Nuclear medicine approach can be first choice for excluding pulmonary embolism in young women 2Health News:Medical, technological advances prompt updating of nuclear medicine technologists' scope of practice 2Health News:Medical, technological advances prompt updating of nuclear medicine technologists' scope of practice 3Health News:Care reforms raise concerns over patient access to GP services 2Health News:Allscripts Named to FORTUNE 100 Fastest-Growing Companies List 2Health News:Allscripts Named to FORTUNE 100 Fastest-Growing Companies List 3Health News:WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana 2Health News:WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana 3
... Severe revision options for the knee and ... modular system for the knee and hip ... that include surgical indication, implant selection, connection ... individual needs. This system addresses the needs ...
The Advance stemmed medial-pivot knee is a revision knee that provides unique and competitive features....
... The NexGen CRA femoral component ... adequate mediolateral, anteroposterior, and varus/valgus ligament ... extensions due to inadequate bone stock. ... available with a PMMA precoat surface. ...
... System will define the state of knee ... less - reducing inventory requirements and increasing ... and cost situations. The GENESIS II ... surgeons creative solutions tomeet todays surgical demands. ...
Medicine Products: